BridgeBio Pharma Inc annual free cash flow for fiscal TTM was -$440 million, an increase of 1.6% from -$447 million in fiscal 2025. All figures are reported results from public filings — no estimates or projections.
| Free Cash Flow (annual) | TTM → 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow (FCF) | ($440M) | ($447M) | ($522M) | ($529M) | ($426M) | ($546M) | ($407M) | ($259M) | ($155M) | ($41M) |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Free Cash Flow (quarterly) | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 |
|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow (FCF) | ($72M) | ($197M) | ($61M) | ($110M) | ($86M) | ($201M) | ($199M) | ($182M) | $72M |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
More BBIO metrics: Revenue · Gross Profit · Operating Income · Net Income · EPS · EBITDA · Shares Outstanding
All BBIO financial statements → Interactive BBIO charts →
About TickerBase · Data methodology & sources · Privacy · Terms